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Carbo/Gem in advanced st IIIb /IV lung cancer, is it really better?
Keren--Rosenberg, Shoshana P.1 Sinatzky, Ekaterina1 Rabkin, Anna1 
Leviov, Michelle1 Shklar, Zoya2 Steiner, Mariana1 
1 Dept. of Oncology Lin Medical Center, Haifa, Israel 2 Dept. of Medi-
cal Oncology, Haifa, Israel 
Between 2002 and 2005 75 pts with NSCLC were treated with carbo-
platin / gemzar, Protocol given consisted of carbo. at AUC 5 on D 1 
and gem. 1000 mg/m2 on D 1 and 8 Q3 weeks.
There were 55 male and 20 female pts, their age ranged from 36 to 84 
years (med 71 ), 
The PS was I in 53 ( 70 .6% ) and II in 22( 29.4%) pts.
27 (36%) pts had stage IIIb disease and 48 (64%) pts had st IV or 
recurrent disease.
Treatment intent was neo - adjuvant in 8 (10.6%) pts and palliative in 
67 (80.4% ) pts.
Cycles received ranged from 1-15 ( med 5 ) percentage given ranged 
from 50 - 100% ( med 80% ).
Myelotoxicity gr III/IV was observed in 35(46.6%) pts and consisted 
mainly in anemia and thrombocytopenia, non hematologic toxicity gr 
III/IV was observed in 8 (10.6%) and consisted mainly in fatigue.
Results: 14 ( 19.7% ) pts were not evaluable for response, PR was 
achieved in 21 (29.5%) pts., MR/SD in 16 (22.5%)pts, NR(no re-
sponse) in 20 (28.1%) pts.
Treatment was stopped in 43 (58.9%) pts due to maximal response, in 
12 ((16.4%) pts due to toxicity and in 18 ( 24.6% )due to other reasons.
Quality of life improved in 12( 7.3%), worsened in 42( 60.8%) and did 
not change in 15( 19%) pts. 
After completion of treatment 1 pt underwent surgery, 7 (9.5% ) pts had 
radiotherapy, 39 ( 53.4% ) pts received a second line treatment and 26 
(35 .6) had supportive care.
At a med. follow up of 10.9 months ( range 0.87 - 41.6 )23 (30.65% ) 
pts. are alive with disease, 51 (68% ) pts are dead of disease.
Kaplan -Mayer survival curves did not show differences among pts. in 
regards with gender or age (below and above 70 ).
Conclusion: This small size retrospective analysis reﬂects other well 
established responses to carbo /gem combination.
Although no formal Quality of life questionnaire were used, striking is 
the fact that according to pts report, quality of life and general well be-
ing worsened in about 70%! This is some-what disappointing in terms 
of real beneﬁt vs toxicity and new more efﬁcient and less toxic drugs 
are desired.
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Gemcitabine - Cisplatin (GC) doublet chemotherapy in the first 
line treatment of the patients (Pts) with advanced non- small cell 
lung cancer (NSCLC): A phase II study
Reza, Salim1 Chowdhury, Qamruzzaman2 Hai, Abdul1 
1 Ahsania Mission Cancer Hospital, Dhaka, Bangladesh 2 National 
Institute of Cancer Research & Hospital, Dhaka, Bangladesh 
Background: Lung Cancer is the leading cause of cancer- related death 
in many countries. NSCLC accounts for about 80% of all lung cancers. 
Despite the progress in imaging and diagnostic procedures, NSCLC 
usually presents as advanced (locally or more frequently disseminated), 
and a small part (around 30%) has to be considered early stage. The ba-
sic treatment of advanced lung cancer is platinum based chemotherapy. 
This phase II study was designed to evaluate the efﬁcacy and safety of 
GC in Pts with advanced NSCLC. 
Methods: From January 2002 to December 2005, 36 Pts with; histo-
logically/ cytologically proven, bidimensionally measurable advanced 
NSCLC, age 18 ~ 75 years with ECOG performance status 0~ 3, no 
prior chemotherapy, life expectancy > 3 months, adequate bone mar-
row, renal, hepatic and haematological values were enrolled. It was 
an open - labeled, non- randomized, single- centered and prospective 
study. The treatment protocol was inj. Gemcitabine 1000 mg/m2 on 
day 1 & day 8 and inj. Cisplatin 75 mg/m2 on day 1 at an interval of 3 
weeks. The efﬁcacy was measured by responses rates and safety was 
measured by adverse events and laboratory blood values. 
Results: This study consisted of 32 (88.89%) male and 4 (11.11%) fe-
male pts. Median age was 55 years. On the Histopathological varieties: 
25 (69.44%) Squamous cell carcinoma, 7 (19.44%) Adenocarcinoma 
and 4 (11.12%) large cell carcinoma were reported. In total, 204 cycles 
chemotherapy were administered with a median of 5.66 cycles per pt 
and 32/ 36 pts were evaluated for responses. The overall response was 
17 (53.12%) with 1 complete and 16 partial responses. 8 (25%) pts 
had stable diseases and 7 (21.88%) had progressive diseases. Overall 
survival was 10.5 months. Grade 3 haematological toxicities were 
observed as follows: neutropenia 32%, anaemia 20% and thrombocyto-
penia 6%. Some non- haematological toxicities including nausea 40%, 
vomiting 25%, mucositis 18%, diarrhoea 20% and peripheral neuropa-
thy 10% were observed. No febrile neurtropenia and fatal events were 
recorded. 
Conclusions: This phase II study supports the use of GC doublet 
combination in chemo naive pts with advanced NSCLC due to its very 
promising anti- tumor activity with well - tolerated toxicities. 
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Pemetrexed single agent chemotherapy in previously treated 
patients with locally advanced or metastatic non-small cell lung 
cancer
Russo, Francesca1 Bearz, Alessandra2 Pampaloni, Gianni1 
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Background: The main objective of this study was to evaluate the 
safety of second-line pemetrexed in Stage IIIB or IV NSCLC. 
Methods: Overall, 95 patients received pemetrexed 500 mg/m2 i.v. 
over Day 1 of a 21-day cycle. Patients also received oral dexametha-
sone, oral folic acid and i.m. vitamin B12 supplementation to reduce 
toxicity. NCI CTC 2.0 was used to rate toxicity. All the adverse events 
were graded in terms of severity and relation to study treatment. Dose 
was reduced in case of toxicity and treatment was delayed for up to 42 
days from Day 1 of any cycle to allow recovering from study drug-
related toxicities.Tumor response was measured using the RECIST 
criteria. 
Results: Patients received a median number of 4 cycles and 97.8% of 
the planned dose. Overall, 75 patients (78.9% of treated) reported at 
least one adverse event: 34 (35.8%) had grade 3 as worst grade and 
only 5 (5.2%) had grade 4. Drug-related events occurred in 57.9% 
of patients. Neutropenia (8.4%) and leukopenia (6.3 %) were the 
most common grade 3/4 hematological toxicities. Grade 3 anemia 
and thrombocytopenia were reported in 3.2% and 2.1% of patients, 
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respectively. Diarrhea (6.3%), fatigue (3.2%) and dyspnea (3.2%) were 
the most common grade 3/4 non-hematological toxicities. The most 
common drug-related toxicities (any grade) were pyrexia (11.6%), 
vomiting, nausea, diarrhea and asthenia (9.5%) and fatigue (8.4%). Tu-
mor Response Rate (CR/PR) in treated patients was 9.2%. The survival 
at 4.5 months (median follow-up) was 79% and the median PFS was 
3.1 months. Twenty patients (21.1%) died mainly because of disease 
progression.
Conclusion: Patients with locally advanced or metastatic NSCLC 
could beneﬁt from second-line pemetrexed, with a low incidence of 
hematological and non-hematological toxicities.
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Association of polymorphisms of ATM and survival in non-small 
cell lung cancer patients treated with platinum combination
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The Ataxia Telangiectasia Mutated (ATM) gene is known to be a pro-
tein kinase that plays a central mediator of responses to DNA double-
strand breaks in cells. Therefore, ATM gene polymorphisms may act as 
important factors predicting the outcome of non-small cell lung cancer 
(NSCLC) patients treated with platinum combination. In order to evalu-
ate the role of ATM gene polymorphisms, seven genotypes of the ATM 
polymorphisms, IVS16-56G>A, IVS17+910G>A, IVS19-657G>A, 
IVS21-76C>T, IVS34-822C>T, IVS62+60A>G, IVS62-973A>C 
were determined in 300 Korean NSCLC patients who were staged as 
IIIA(n=48), IIIB (n=93) and IV (n=159). One-, three-, ﬁve-year sur-
vival was shown to be 57.6%, 11.7%, 4.7% respectively. Clinical stage, 
performance status, body weight loss (>5%) or response status to the 
treatment was correlated signiﬁcantly with survival (P=0.027, 0.038, 
0.076 <0.001 respectively). The frequencies for major and minor allele 
were as followings: 56% and 44% for IVS16-56G>A, 88% and 12% 
for IVS17+910G>A, 68% and 32% for IVS19-657G>A, 61% and 39% 
for IVS21-76C>T, 64% and 36% for IVS34-822C>T, 52% and 48% for 
IVS62+60A>G, 60% and 40% for IVS62-973A>C. When the effects of 
selected ATM genotypes were evaluated, any ATM genotype was not 
shown to have association with survival (log rank P=0.317 for IVS16-
56G>A, 0.451 for IVS17+910G>A, 0.520 for IVS19-657G>A, 0.542 
for IVS21-76C>T, 0.272 for IVS34-822C>T, 0.371 for IVS62+60A>G, 
0.470 for IVS62-973A>C). Therefore, our results suggest that poly-
morphisms of the ATM gene can not confer prognostic relevance in 
NSCLC patients treated with platinum combination. 
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Multi-institutional phase ii study of carboplatin/gemcitabine 
combination chemotherapy in elderly patients (Pts) with advanced 
non-small cell lung cancer (NSCLC)
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Background: Because elderly pts may tolerate platinum-based combi-
nation chemotherapy poorly, single-agent chemotherapy is selected for 
the treatment regimen. However, retrospective subgroup analyses have 
consistently indicated that elderly pts indeed beneﬁt from platinum-
based combination chemotherapy as well as their younger counterparts. 
This phase II study evaluated the efﬁcacy and safety of carboplatin/
gemcitabine combination chemotherapy in elderly pts with advanced 
NSCLC.
Methods: Fifty-four pts aged more than 70 years old (median, 77; 
range, 70-88) with previously untreated advanced NSCLC were 
enrolled on this trial. Additional criteria included the presence of mea-
surable lesions, an Eastern Cooperative Oncology Group performance 
status of 0 or 1, and adequate organ function. Pts received carboplatin 
at an area under the curve of 4 mg/ml/min on the ﬁrst day and gem-
citabine at 1000 mg/m2 on the ﬁrst and eighth day of consecutive 3 
week periods. The primary endpoint was to determine the objective 
response rate of this platinum-doublet regimen. The RECIST criteria 
were used to measure response. 
Results: Enrolled pts included 15/39 with stage IIIB/IV diseases. Fifty-
one out of enrolled pts were eligible for efﬁcacy and safety analyses. 
The median number of treatment cycles was 4 (range, 1-7). Fifteen 
partial responses (response rate: 29%) were obtained. The median TTP 
was 3.9 months, and median overall survival was 15.9 months. Hema-
tological toxicities of grade 3/4 included leukopenia (46%), neutrope-
nia (72%) and thrombocytopenia (50%). Non-hematological toxicities 
of grade 3/4 included nausea (6%), appetite loss (7%), fatigue (7%) and 
infection (9%). 
Conclusion: The combination carboplatin-gemcitabine at these doses 
has shown activity with a favorable toxicity proﬁle for ﬁt elderly pts 
with advanced NSCLC.
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Immediate versus delayed docetaxel after first-line therapy with 
gemcitabine plus carboplatin in advanced non-small-cell lung 
cancer: A Phase III trial report with survival update
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Background: Gemcitabine plus carboplatin (GC) therapy is active as 
ﬁrst-line treatment in advanced non-small-cell lung cancer (NSCLC). 
For nonprogressing patients, the timing of second-line chemotherapy 
for optimum clinical beneﬁt is uncertain. Docetaxel (D) is approved for 
second-line therapy in advanced NSCLC. This Phase III, randomized 
trial assessed the efﬁcacy and safety of D administered either immedi-
ately after initial GC therapy or upon disease progression (PD). 
Methods: Patients enrolled had either Stage IIIB with pleural effusion 
or Stage IV NSCLC. Prior chemotherapy for NSCLC was excluded. 
Gemcitabine 1000 mg/m2 was administered on Days 1, 8 followed by 
carboplatin AUC 5 on Day 1. After four 21-day cycles, nonprogres-
sors were randomized to either immediate D group (D 75 mg/m2 on 
Day 1 every 21 days, maximum of 6 cycles) or delayed D group (best 
